Company: SPEG
Filing Date: 2025-01-21
Form Type: CORRESP
Source: 0001213900-25-005100
Chunk: 4

Company: Silver Pegasus Acquisition Corp.
Filing Date: 2025-01-21
Form: CORRESP
Chunk 4
---
.

<div align='center'>3</div>

Additional Financing, page 8

12. Please disclose how the terms of additional financings, including forward purchase and backstop agreements mentioned elsewhere, may impact unaffiliated security holders, as required by Item 1602(b)(5) of Regulation S-K.

Response: The Company revised
the disclosure in the S-1 to address the Staff’s comment. Please see page 14 of the S-1.

Conflicts of Interest, page 30

13. Please add disclosure of the conflicts of interest relating to the fees, repayment of loans, and reimbursements of expenses that will be paid to officers and directors affiliated with the sponsor upon completion of a de-SPAC transaction. Please also disclose the potential conflicts of interest due to the potential payment of finder’s fees, advisory fees, consulting fees, or success fees for any services rendered for completion of the initial business combination, as referenced on page 30. Please also revise to disclose conflicts of interest that may arise in the event that you seek to complete your initial business combination with a company that is affiliated with your sponsor, officers or directors, as referenced on page 7. See Item 1602(b)(7) of Regulation S-K.

Response: The Company revised
the disclosure in the S-1 to address the Staff’s comment. Please see pages 13, 35-36 and 107 of the S-1, and the Risk Factor on page
72, “Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.”

The non-managing sponsor investors have expressed an interest to purchase substantially all of the units in this offering, page 71

14. Given the indications of interest from the non-managing sponsor investors to purchase 100% of this offering, please explain the statement that you “do not expect any purchase of units by the non-managing sponsor investors to negatively impact [y]our ability to meet Nasdaq listing eligibility requirements.”

Response: The Company revised
the disclosure in the S-1 to address the Staff’s comment. Please see the Cover Page and pages 24 and 146 of the S-1.

Dilution, page 89

15. Please expand your disclosure to describe each material potential source of future dilution. Your revisions should address, but not be limited to, founder shares anti-dilution rights, shares that may be issued in connection with the closing of your initial business combination, and up to